Supreme Court Keeps Abortion Pill Mifepristone in Play Amid Legal Tug-of-War
The Supreme Court just hit the brakes on a potential abortion pill ban, keeping mifepristone accessible for now. Justice Samuel Alito’s order on Monday means women can still snag this crucial medication through pharmacies or by mail, dodging the need for an in-person doctor's visit. This ruling effectively halts a federal appeals court's restrictions from kicking in right away.
As the high court dives into yet another abortion-related showdown, it’s a stark reminder of the seismic shifts since Roe v. Wade was overturned four years ago, triggering outright bans in over a dozen states. The latest legal drama stems from Louisiana’s lawsuit, which aims to dismantle the FDA’s established guidelines for prescribing mifepristone.
Louisiana argues that the current policy undermines its state ban and raises questions about the drug's safety. Mifepristone, first greenlit in 2000, has consistently been deemed safe and effective by FDA experts. Yet, lower courts have sided with Louisiana, suggesting they might win this battle. A three-judge panel from the 5th U.S. Circuit Court of Appeals even ruled that access via mail and telehealth should be put on ice while the case unfolds.
This medication is typically used alongside misoprostol for abortions, with medication abortions making up nearly two-thirds of all procedures in the U.S. in 2023—the latest year for which we have data. The current legal fracas echoes a similar case that reached the Supreme Court three years back when physicians opposed to abortion sought to restrict access to mifepristone after Roe was overturned.
Back then, the Supreme Court blocked the 5th Circuit's ruling despite dissent from Alito and Justice Clarence Thomas. In 2024, they unanimously dismissed the doctors’ lawsuit, stating they lacked standing to sue. Now, mainstream medical organizations, pharmaceutical giants, and Democratic lawmakers are sounding alarms against any limitations on mifepristone access, warning that a ruling favoring abortion opponents could disrupt the entire drug approval process.
The FDA has already relaxed several restrictions on mifepristone, including who can prescribe it and how it’s dispensed. Yet, anti-abortion advocates have been challenging its safety for over 25 years, filing numerous petitions and lawsuits claiming the FDA ignored safety concerns.
Interestingly, Trump’s administration has remained unusually silent during this Supreme Court saga, opting not to file a brief on what direction the court should take despite the federal regulations at stake. This silence puts Trump’s Republican administration in a tight spot—caught between the backing of anti-abortion factions and public opinion that generally favors abortion rights.
Both sides interpret this quiet as a nod to the appellate ruling. Alito, who oversees emergency appeals from Louisiana, also authored the 2022 decision that stripped abortion of its constitutional protection, handing control back to the states.
